AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20102552 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 74
Study 20102552 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 74
Study 17870203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb extract (20 mg kg(‐1) once a day) for 6 weeks
Number of subjects: 80
Study 17870203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch) for 6 weeks
Number of subjects: 80
Study 17870203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb extract
Number of subjects: 80
Study 15802870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban and clopidogrel pretreatment for 48 hours before intervention
Number of subjects: 47
Study 15802870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban and clopidogrel pretreatment
Number of subjects: 47
Study 15802870 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no tirofiban and clopidogrel)
Number of subjects: 47
Study 15802870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 14666763 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi-supplementing and blood-activating (QSBA) therapy
Number of subjects: 68
Study 14666763 — intervention group
Group type: COMPARATOR
Intervention: Neurotrophic agents
Number of subjects: 68
Study 10953421 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxin treatment for six months
Number of subjects: 20
Study 10953421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9064258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal stage disease (12 specimens)
Number of subjects: 42
Study 9064258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal stage disease
Number of subjects: 42
Study 9064258 — intervention group
Group type: COMPARATOR
Intervention: Normal palmar fascia
Number of subjects: 42
Study 9064258 — intervention group
Group type: COMPARATOR
Intervention: Stage IV disease
Number of subjects: 42
Study 9064258 — intervention group
Group type: COMPARATOR
Intervention: Nodal or cord-stage of Dupuytren's disease
Number of subjects: 42
Study 1624967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 6500
Study 1624967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study 6385316 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheteric partial splenic embolization (PSE)
Number of subjects: 53
Study 6385316 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy (SX)
Number of subjects: 53
Study 29931571 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated corneal cross-linking (CXL)
Number of subjects: 23
Study 29931571 — intervention group
Group type: COMPARATOR
Intervention: Conventional corneal cross-linking (CXL)
Number of subjects: 23
Study 29460388 — intervention group
Group type: EXPERIMENTAL
Intervention: pdFX (plasma-derived factor X concentrate) 25 IU kg-1 on-demand
Number of subjects: 10
Study 26808034 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1:1 ratio of plasma-platelet-red blood cell
Number of subjects: 680
Study 26808034 — intervention group
Group type: COMPARATOR
Intervention: 1:1:2 ratio of plasma-platelet-red blood cell
Number of subjects: 680
Study 24258152 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-course tourniquet strategy
Number of subjects: 64
Study 24258152 — intervention group
Group type: COMPARATOR
Intervention: Whole-course tourniquet strategy
Number of subjects: 64
Study 24258152 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 22997787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint application combined with routine treatment of western medicine
Number of subjects: 63
Study 22997787 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of western medicine
Number of subjects: 63
Study 19756027 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilned oats
Number of subjects: 31
Study 19756027 — intervention group
Group type: EXPERIMENTAL
Intervention: Unkilned oats
Number of subjects: 31
Study 17521315 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic training (N)
Number of subjects: 8
Study 17521315 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic training (H)
Number of subjects: 8
Study 11097143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-resistant tablets (500 mg)
Number of subjects: 200
Study 11097143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tablets (1000 mg single dose)
Number of subjects: 200
Study 11097143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administrations of mesalazine
Number of subjects: 200
Study 11097143 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of mesalazine suppository
Number of subjects: 200
Study 11097143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of mesalazine
Number of subjects: 200
Study 9506005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime (2-g intravenous dose)
Number of subjects: 0
Study 9506005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpirome (2-g intravenous dose)
Number of subjects: 0
Study 8478756 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive physical therapy for 8 weeks
Number of subjects: 50
Study 8478756 — intervention group
Group type: COMPARATOR
Intervention: No physical therapy (Control)
Number of subjects: 50
Study 3510422 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 30
Study 3510422 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 29153250 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental skills and FLS training (MSC group)
Number of subjects: 24
Study 29153250 — intervention group
Group type: COMPARATOR
Intervention: Only FLS training (control group)
Number of subjects: 24
Study 26898621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab + Docetaxel (RAM + DTX)
Number of subjects: 1253
Study 26898621 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Docetaxel (PL + DTX)
Number of subjects: 1253
Study 25143491 — intervention group
Group type: EXPERIMENTAL
Intervention: e-beam sterilization (high dose 17.1 to 21.0 kGy)
Number of subjects: 80
Study 25143491 — intervention group
Group type: EXPERIMENTAL
Intervention: e-beam sterilization (low dose 9.2 to 12.2 kGy)
Number of subjects: 80
Study 25143491 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma irradiation (17.1 to 21.0 kGy)
Number of subjects: 80
Study 25143491 — intervention group
Group type: COMPARATOR
Intervention: nonsterilized controls
Number of subjects: 80
Study 22442431 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 198
Study 22442431 — intervention group
Group type: COMPARATOR
Intervention: Interferon β‐1a (IFNβ‐1a)
Number of subjects: 198
Study 20528696 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA + HA/GTR
Number of subjects: 24
Study 20528696 — intervention group
Group type: COMPARATOR
Intervention: SFA
Number of subjects: 24
Study 18761816 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomization inhalation of budesonide and terbutaline
Number of subjects: 0
Study 18761816 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 15908196 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel 85 mg/m2 i.v. on day 1 and cisplatin 40 mg/m2 i.v. on days 1 and 2 (arm A)
Number of subjects: 83
Study 15908196 — intervention group
Group type: COMPARATOR
Intervention: cisplatin 100 mg/m2 i.v. on day 1 followed by 5‐fluorouracil 1000 mg/m2 in 24 h continuous infusion for 5 d (arm B)
Number of subjects: 83
Study 12595863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 130
Study 12595863 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (40 mg daily)
Number of subjects: 130
Study 10563619 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 201
Study 10563619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 8907785 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 0
Study 8907785 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 0
Study 1859044 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral prednisone 13, 7, and 1 hour before and 50 mg intramuscular diphenhydramine 1 hour before procedures (group I)
Number of subjects: 149
Study 1859044 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg oral cimetidine one hour before procedure in addition to the other regimen (group II)
Number of subjects: 149
Study 1859044 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of oral prednisone, 300 mg oral cimetidine, and 25 mg oral ephedrine one hour before procedures (group III)
Number of subjects: 149
Study 1859044 — intervention group
Group type: EXPERIMENTAL
Intervention: Provocative dosing regimen in a separate group of ten patients whose previous reactions to RCM were life threatening (shock)
Number of subjects: 149
Study 30964964 — intervention group
Group type: EXPERIMENTAL
Intervention: G2‐E4 (ESWT at 4 weeks)
Number of subjects: 36
Study 30964964 — intervention group
Group type: EXPERIMENTAL
Intervention: G3‐E8 (ESWT at 8 weeks)
Number of subjects: 36
Study 30964964 — intervention group
Group type: EXPERIMENTAL
Intervention: G4‐E16 (ESWT at 16 weeks)
Number of subjects: 36
Study 30964964 — intervention group
Group type: COMPARATOR
Intervention: G1‐S (sham ESWT)
Number of subjects: 36
Study 28237629 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 42
Study 28237629 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 42
Study 25873233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fluoroscopy-based navigation combined with conventional fluoroscopy (NAV group)
Number of subjects: 40
Study 25873233 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy (FLUORO group)
Number of subjects: 40
Study 23174629 — intervention group
Group type: EXPERIMENTAL
Intervention: Life coaching and pharmacist counseling
Number of subjects: 190
Study 23174629 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 190
Study 23174629 — intervention group
Group type: EXPERIMENTAL
Intervention: Life coaching and pharmacist counseling (greater number of sessions)
Number of subjects: 190
Study 21332635 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (1- or 2-mg Prostin E2 vaginal gel)
Number of subjects: 165
Study 21332635 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 165
Study 21332635 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 tablets (3-mg Prostin E2 vaginal tablets)
Number of subjects: 165
Study 18992272 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient activation (flash suppression)
Number of subjects: 0
Study 18992272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained activation (binocular rivalry)
Number of subjects: 0
Study 18992272 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational modeling
Number of subjects: 0
Study 18992272 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral surround activation
Number of subjects: 0
Study 18992272 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset of contralateral surround
Number of subjects: 0
Study 18834620 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopic hysterectomy (RALH) with lymphadenectomy (LA)
Number of subjects: 162
Study 18834620 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH) with lymphadenectomy (LA)
Number of subjects: 162
Study 15921508 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 796
Study 15921508 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 796
Study 15921508 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 796
Study 15921508 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy
Number of subjects: 796
Study 15921508 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 796
Study 15921508 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment
Number of subjects: 796
Study 12243012 — intervention group
Group type: EXPERIMENTAL
Intervention: Palacos mixed in vacuum
Number of subjects: 72
Study 12243012 — intervention group
Group type: COMPARATOR
Intervention: Palacos mixed conventionally (Control)
Number of subjects: 72
Study 10416052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone (Q10) 90 mg/day
Number of subjects: 63
Study 10416052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinone (Q10) 180 mg/day
Number of subjects: 63
Study 10416052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7589772 — intervention group
Group type: EXPERIMENTAL
Intervention: SCMC‐Lys 900 mg three times a day (adults) or SCMC‐Lys 270 mg three times a day (children)
Number of subjects: 26
Study 7589772 — intervention group
Group type: COMPARATOR
Intervention: ABX 33 mg three times a day (adults) or ABX 10 mg four times a day (children)
Number of subjects: 26
Study 1693042 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (0.3 g/kg) and Tryptophan (0.1 g/kg) for 2 to 17 weeks
Number of subjects: 9
Study 1693042 — intervention group
Group type: COMPARATOR
Intervention: Double-blind cross-over trial
Number of subjects: 9
Study 7251235 — intervention group
Group type: EXPERIMENTAL
Intervention: Palerol
Number of subjects: 19
Study 7251235 — intervention group
Group type: EXPERIMENTAL
Intervention: Litalgin
Number of subjects: 19
Study 31739785 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet on fever and management of fever in children
Number of subjects: 100
Study 31739785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information leaflet)
Number of subjects: 100
Study 28091362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 28091362 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 100 μg (VP100)
Number of subjects: 74
Study 28091362 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 250 μg (VP250)
Number of subjects: 74
Study 26054865 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacer injection (SpaceOAR system)
Number of subjects: 222
Study 26054865 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 222
Study 23365108 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-berry purée with white bread (WB)
Number of subjects: 20
Study 23365108 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-berry purée with rye bread (RB)
Number of subjects: 20
Study 23365108 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberries with WB
Number of subjects: 20
Study 23365108 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry mixture with WB
Number of subjects: 20
Study 23365108 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry mixture with RB
Number of subjects: 20
Study 23365108 — intervention group
Group type: COMPARATOR
Intervention: WB without berries (reference)
Number of subjects: 20
Study 23365108 — intervention group
Group type: COMPARATOR
Intervention: RB without berries (reference)
Number of subjects: 20
Study 20979541 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Number of subjects: 1682
Study 20979541 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Number of subjects: 1682
Study 19389471 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins C and E supplementation
Number of subjects: 0
Study 19389471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17472864 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cycle combined hormonal contraception
Number of subjects: 0
Study 17472864 — intervention group
Group type: COMPARATOR
Intervention: Traditional cyclic combined hormonal contraception
Number of subjects: 0
Study 15041615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% with fentanyl 0.0002%
Number of subjects: 350
Study 15041615 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.1% with fentanyl 0.0002%
Number of subjects: 350
Study 15041615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 350
Study 15041615 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 350
Study 11586009 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole 1% vanishing cream
Number of subjects: 9
Study 11586009 — intervention group
Group type: COMPARATOR
Intervention: Vehicle only
Number of subjects: 9
Study 11586009 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 9
Study 9128234 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined operating room supply pack
Number of subjects: 139
Study 9128234 — intervention group
Group type: COMPARATOR
Intervention: Standard operating room supply pack (Control)
Number of subjects: 139
Study 9128234 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Streamlined and Control)
Number of subjects: 139
Study 8201126 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg D-fenfluramine
Number of subjects: 10
Study 8201126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3322837 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar HBS (200 mg levodopa plus 50 mg benserazide)
Number of subjects: 17
Study 3322837 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar HBS (3 capsules of 125 mg)
Number of subjects: 17
Study 3322837 — intervention group
Group type: COMPARATOR
Intervention: Standard Madopar (2 capsules of 125 mg)
Number of subjects: 17
Study 3322837 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar HBS
Number of subjects: 17
Study 31944252 — intervention group
Group type: EXPERIMENTAL
Intervention: Talus mobilization intervention (6 sessions of manual therapy)
Number of subjects: 36
Study 31944252 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 36
Study 28818486 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-ads produced during media literacy lesson
Number of subjects: 40
Study 27974055 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic (galacto-oligosaccharide mixture)
Number of subjects: 29
Study 27974055 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 29
Study 24256848 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF-CCRT
Number of subjects: 439
Study 24256848 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-CCRT
Number of subjects: 439
Study 24256848 — intervention group
Group type: COMPARATOR
Intervention: CCRT alone
Number of subjects: 439
Study 23523116 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg AZD2423
Number of subjects: 133
Study 23523116 — intervention group
Group type: EXPERIMENTAL
Intervention: 150mg AZD2423
Number of subjects: 133
Study 23523116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 20492735 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA (saturated fatty acids)
Number of subjects: 18
Study 20492735 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA (polyunsaturated fatty acids)
Number of subjects: 18
Study 20492735 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA (monounsaturated fatty acids)
Number of subjects: 18
Study 18491179 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical BoNTA (CosmeTox) cream (2 U/ml)
Number of subjects: 40
Study 18491179 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (without BoNTA)
Number of subjects: 40
Study 15750370 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture on point P6 (Neiguan)
Number of subjects: 220
Study 15750370 — intervention group
Group type: COMPARATOR
Intervention: Placebo/sham acupuncture on a virtual point 1 cm proximal and lateral to P6
Number of subjects: 220
Study 11834955 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12 Health Status Questionnaire
Number of subjects: 0
Study 11834955 — intervention group
Group type: COMPARATOR
Intervention: SF-39 Health Status Questionnaire
Number of subjects: 0
Study 10744129 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg alpha-tocopherol per day
Number of subjects: 31
Study 10744129 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg alpha-tocopherol per day
Number of subjects: 31
Study 10744129 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg alpha-tocopherol per day
Number of subjects: 31
Study 7730690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 2.5 mg twice daily
Number of subjects: 139
Study 7730690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 2389649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% scalp infiltration
Number of subjects: 20
Study 2389649 — intervention group
Group type: COMPARATOR
Intervention: Normal saline scalp infiltration
Number of subjects: 20
Study 7308334 — intervention group
Group type: EXPERIMENTAL
Intervention: OD treatment group (advice and medication for OD)
Number of subjects: 62
Study 7308334 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment, advised to recheck OD in 2 months)
Number of subjects: 62
Study 29363448 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced variant of the UV program
Number of subjects: 0
Study 29363448 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic variant of the UV program
Number of subjects: 0
Study 29363448 — intervention group
Group type: COMPARATOR
Intervention: Control groups (no intervention)
Number of subjects: 0
Study 26912555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (3 mg/d; serum target levels of 5‐10 ng/ml) added on to conventional therapy
Number of subjects: 41
Study 26912555 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 41
Study 24246498 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment in CMT1A patients
Number of subjects: 189
Study 24246498 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory dysfunction
Number of subjects: 189